Aim: Pseudomonas aeruginosa (PsA) is a common pathogen in cystic fibrosis (CF).
The primary objective of this study was to utilize pharmacokinetic data from adult CF patients that received intravenous amikacin to determine the probability of target attainment for PsA. We hypothesized goal peaks and troughs were being attained with the recommended dosing. The secondary objective assessed for patient safety by reviewing for evidence of acute kidney injury with the use of amikacin. We included observations about clinical outcomes including forced expiratory volume in one second (FEV 1 ) and weight gain as they are important factors in trending response to antimicrobial therapy in the management of an acute pulmonary exacerbation.
| MATERIALS AND METHODS
This was a single-center, non-randomized, retrospective cohort study of patients >18 years of age with CF that received intravenous amikacin and had therapeutic drug monitoring completed as an inpatient. Therapeutic drug monitoring was defined as having at least two amikacin serum concentrations drawn within one dosing interval.
The same patient could be included in the analysis multiple times accounting for additional therapeutic drug monitoring of amikacin. Serum creatinine at admission, mg/dL (mean ± std dev) 0.67 ± 0.19 FEV 1 Prior to admission, % (mean ± std dev) 31 ± 13.8
Acute pulmonary exacerbations per year, (mean ± std dev) Inpatient-4.5 ± 3. 
| RESULTS
This study included six patients with pharmacokinetic monitoring parameters totaling 14 courses of amikacin. All patients were
Caucasian, a majority were male, with a median age of 27 years old (Tables 1 and 2 ). Pulmonary function testing at baseline varied amongst patients with FEV 1 percent predicted at most recent clinic visit prior to admission ranging from a low of 12% to a high of 52%. All patients had at least one documented PsA positive sputum culture during their course of amikacin therapy. Calculated pharmacokinetic parameters were determined for each course of amikacin therapy (Table 3 ).
The average empiric dose of amikacin administered during our study period was 24.3 ± 14.6 mg/kg (Table 1) . MIC distribution of PsA revealed 48% (n = 55/115) of isolates were susceptible to amikacin using the Clinical and Laboratory Standards Institute breakpoint of ≤16 mg/L (Figure 1) . 15 When the average dose of amikacin with standard deviation was simulated, using isolates with a MIC ≤16 mg/L distribution, the goal peak:MIC ratio ≥8 was achieved at a rate of 37% (median peak:MIC ratio 5.87; IQR 3.05-10.96) (Figure 2 ). When MCS with set MIC values was performed, doses of 45 mg/kg/day were needed to achieve target concentrations 90% of the time for a MIC of 8 mg/L (Table 4) . MCS using the isolates with a MIC ≤16 mg/L distribution required doses of 66 mg/kg/day to achieve target concentrations 90% of the time. This is representative of utilizing empiric therapy for PsA isolates that are known to be susceptible without a MIC available.
Of the 14 courses of amikacin, 1 patient (7.14%) had an increase of 1.5 times their baseline serum creatinine within 7 days of the first dose of amikacin, therapy was continued and serum creatinine returned to baseline within 24 h. All patients received at least one additional nephrotoxic medication, with beta-lactams used concomitantly during 13 of 14 courses of amikacin (Table 1) .
Patients gained an average of 2.72 ± 7.11 kg from prior to initiation of amikacin therapy to their first weight recorded after completion of their course of amikacin. Pre-and post-acute pulmonary exacerbation FEV 1 measurements were available for eight courses of amikacin; four patients (50%) had an increase in FEV 1 with an average change of 10.25 ± 3.3% and six patients (75%) returned to within 10%
of their pre-admission baseline best FEV 1 .
| DISCUSSION
To our knowledge, this is the first study to evaluate dosing regimens of amikacin based on pharmacokinetics solely in adult patients with CF and the achievement of pharmacodynamic target attainment. Published studies of anti-pseudomonal aminoglycoside use in CF patients primarily consists of pediatric populations. 3 Staubes et al published a recent study in Pharmacotherapy evaluating tobramycin therapy in adult CF patients. 5 Of 186 patient encounters, 41% achieved the target peak concentration of 30-50 mg/L and 62% achieved the target extrapolated trough concentration of <0.05 mg/L. 5 The authors demonstrated that current practice of dosing tobramycin may not be optimally treating CF patients with PsA infections. 5 As adult patients with CF are prone to these difficult-to-treat multi-drug resistant infections, they often receive many courses of tobramycin throughout their lifetime. In some cases, resistance develops to tobramycin therefore amikacin is utilized as the aminoglycoside for treatment of acute pulmonary exacerbations. Although not as predictive in patients Limitations of this study include that it is retrospective, with a small sample size. The sample size was reduced due to a shortage of amikacin during a portion of the study time frame. Although all patients included in the study had sputum cultures positive for PsA, chart documentation revealed three patients received amikacin for atypical mycobacterial (n = 2) or Escherichia coli (n = 1) in addition to PsA coverage. One of the two patients receiving amikacin for atypical mycobacterium infection was receiving long-term treatment during continuation phase. This patient had a similar clearance to other patients included in the study and did not demonstrate accumulation.
As mentioned above, our average dose of amikacin was below the recommended range endorsed by the CFF guidelines. We hypothesize this may be attributed to the indication for these varying infections.
In conclusion, our data suggests it may not be clinically feasible to 
